Obesity Research PEPTIDE
Retatrutide 60mg
GIP, GLP-1, and glucagon receptor triple agonist for advanced obesity research.
Molecular & Physicochemical Properties
| HPLC Purity |
> 99% |
| Molecular Formula |
C221H342N46O68 |
| Molecular Weight |
4731.33 g/mol |
| Physical Appearance |
White Lyophilized Powder |
| Recommended Storage |
2°C to 8°C, protected from light and freezing |
Documented Research Indications & In-Vitro Action
-
Triple receptor agonist (GIP/GLP-1/Glucagon)
-
Advanced modulation of energy expenditure
-
Highest efficacy ceiling in metabolic research
-
Significant impact on hepatic lipid markers
-
Optimized for obesity and NASH research
Scientific Monograph & Mechanistic Overview
Retatrutide is a potential groundbreaking "triple agonist" peptide that targets three key metabolic receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1), and the glucagon receptor.
This multi-pathway approach is being studied for its unprecedented ability to modulate energy expenditure and adipocyte regulation. By engaging the glucagon receptor alongside the incretin receptors, Retatrutide research explores a higher ceiling for metabolic efficiency compared to dual agonists.
